Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Merck
Boehringer Ingelheim
McKinsey
McKesson
Johnson and Johnson
Express Scripts

Last Updated: January 27, 2023

Sumatriptan succinate - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What are the generic drug sources for sumatriptan succinate and what is the scope of patent protection?

Sumatriptan succinate is the generic ingredient in eight branded drugs marketed by Meridian Medcl, Glaxosmithkline, Antares Pharma Inc, Caplin, Dr Reddys, Eugia Pharma, Fresenius Kabi Usa, Hikma, Mylan Labs Ltd, Par Pharm, Par Sterile Products, Sandoz Inc, Steriscience, Sun Pharm, Teva Parenteral, Teva Pharms Usa, West-ward Pharms Int, Wockhardt, Zydus, Endo Ventures Ltd, Currax, Upsher Smith Labs, Teva Branded Pharm, Aurobindo Pharma, Corepharma, Dr Reddys Labs Inc, Fosun Pharma, Hikma Pharms, Mylan, Orbion Pharms, Roxane, Sun Pharm Inds, Sun Pharm Inds Ltd, Teva, and Watson Labs, and is included in forty NDAs. There are thirty-nine patents protecting this compound and two Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Sumatriptan succinate has four hundred and nineteen patent family members in thirty-one countries.

There are seventeen drug master file entries for sumatriptan succinate. Thirty-two suppliers are listed for this compound. There are four tentative approvals for this compound.

Drug Prices for sumatriptan succinate

See drug prices for sumatriptan succinate

Drug Sales Revenue Trends for sumatriptan succinate

See drug sales revenues for sumatriptan succinate

Recent Clinical Trials for sumatriptan succinate

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
The Second Affiliated Hospital of Kunming Medical UniversityPhase 3
Second Hospital of Jilin UniversityPhase 3
Beijing Friendship HospitalPhase 3

See all sumatriptan succinate clinical trials

Generic filers with tentative approvals for SUMATRIPTAN SUCCINATE
Applicant Application No. Strength Dosage Form
See Plans and PricingSee Plans and PricingEQ 100MG BASETABLET;ORAL
See Plans and PricingSee Plans and PricingEQ 50MG BASETABLET;ORAL
See Plans and PricingSee Plans and PricingEQ 25MG BASETABLET;ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

US Patents and Regulatory Information for sumatriptan succinate

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Zydus SUMATRIPTAN SUCCINATE sumatriptan succinate INJECTABLE;SUBCUTANEOUS 090310-001 Aug 11, 2010 DISCN No No See Plans and Pricing See Plans and Pricing See Plans and Pricing
Currax ONZETRA XSAIL sumatriptan succinate POWDER;NASAL 206099-001 Jan 27, 2016 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Roxane SUMATRIPTAN SUCCINATE sumatriptan succinate TABLET;ORAL 078241-001 Aug 10, 2009 DISCN No No See Plans and Pricing See Plans and Pricing See Plans and Pricing
Sun Pharm Inds Ltd SUMATRIPTAN SUCCINATE sumatriptan succinate TABLET;ORAL 076554-002 Aug 10, 2009 AB RX No No See Plans and Pricing See Plans and Pricing See Plans and Pricing
Endo Ventures Ltd SUMAVEL DOSEPRO sumatriptan succinate INJECTABLE;SUBCUTANEOUS 022239-001 Jul 15, 2009 DISCN Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Currax ONZETRA XSAIL sumatriptan succinate POWDER;NASAL 206099-001 Jan 27, 2016 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for sumatriptan succinate

International Patents for sumatriptan succinate

Country Patent Number Title Estimated Expiration
Japan 4688416 See Plans and Pricing
Japan 2011524901 See Plans and Pricing
Canada 2727927 PHARMACOCINETIQUE D'UNE ADMINISTRATION IONTOPHORETIQUE DE SUMATRIPTAN (PHARMACOKINETICS OF IONTOPHORETIC SUMATRIPTAN ADMINISTRATION) See Plans and Pricing
Japan 4959906 See Plans and Pricing
European Patent Office 2136865 ADMINISTRATION NASALE (NASAL DELIVERY) See Plans and Pricing
Canada 2918226 DISPOSITIF D'ADMINISTRATION NASALE SERVANT A ADMINISTRER UNE SUBSTANCE DANS UNE CAVITE NASALE D'UN SUJET (NASAL DELIVERY DEVICE FOR DELIVERING SUBSTANCE TO A NASAL CAVITY OF A SUBJECT) See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Moodys
Medtronic
Boehringer Ingelheim
McKinsey
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.